Tau Workshop Program

Monday, March 28

9:00–9:30 am  Welcome and Introduction  
Lennart Mucke, MD, GIND and University of California, San Francisco (UCSF), and Pierluigi Nicotera, MD, PhD, DZNE Bonn

9:30–10:00 am  “Tauopathies – A Clinical Perspective”  
Bruce Miller, MD, UCSF

10:00–10:30 am  “Tau-Related Therapeutic Initiatives”  
Peter Davies, PhD, Albert Einstein College of Medicine

10:30–10:45 am  Break

10:45–11:15 am  “Tau Pathology Through the Looking Glass: Are Tangles as Toxic as They Look?”  
Tara Spires-Jones, DPhil, Harvard University

11:15–11:45 am  “Tau Conformation, Oligomerization, and Toxicity in AD: Evidence for Inhibition of Axonal Transport”  
Lester Binder, PhD, Northwestern University

11:45 am–12:15 pm  TBA  
Michel Goedert, MD, PhD, MRC Cambridge

12:30–1:30 pm  Lunch Break

1:30–2:00 pm  “Pathogenic Mechanisms in Tauopathy”  
Karen Duff, PhD, Columbia University

2:00–2:30 pm  “From I2PP2A/SET Cleavage to Neurodegeneration: A Pathogenic Mechanism of Alzheimer disease”  
Khalid Iqbal, PhD, New York State Institute

2:30–2:45 pm  Break

2:45–3:15 pm  “The Turnover and Toxicity of Truncated Tau”  
Gail Johnson, PhD, University of Rochester

3:15–3:45 pm  “Exploiting the Diversity of the Chaperone Repertoire to Treat Diseases of Aging”  
Chad Dickey, PhD, University of South Florida

3:45–4:00 pm  Break

4:00–4:30 pm  “Brain-Penetrant Microtubule Stabilizing Compounds as Potential Therapeutic Agents for Tauopathies”  
Kurt Brunden, PhD, University of Pennsylvania

4:30–5:00 pm  TBA  
Eckhard Mandelkow, PhD, DZNE Bonn
Tuesday, March 29

9:00–9:30 am  “Functionally Meaningful Outcome Measures in Tauopathies and Related Models”
                Pierluigi Nicotera, MD, PhD, DZNE Bonn

9:30–10:00 am  TBA
                Lennart Mucke, MD, GIND and UCSF

10:00–10:30 am “Modes of Tau Toxicity”
                Jürgen Götz, PhD, University of Sydney

10:30–10:45 am Break

10:45–11:15 am TBA
                Eva-Maria Mandelkow, MD, PhD, DZNE Bonn

11:15–11:45 am “ApoE4 Causes Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits”
                Yadong Huang, MD, PhD, GIND and UCSF

11:45 am–12:15 pm TBA
                Li Gan, PhD, GIND and UCSF

12:15–1:15 pm Lunch Break

1:30–2:00 pm  “Tau-Dependent Cytotoxicity and Prion-Like Properties of Aβ Oligomers Seeded by Pyroglutamate-Modified Aβ”
                George Bloom, PhD, University of Virginia

2:00–2:30 pm  “SUT-2/MSUT2 Influences Tau Aggregation and Neurotoxicity”
                Brian Kraemer, PhD, University of Washington

2:30–2:45 pm  Break

2:45–3:15 pm  “Loss of Tau Sensitizes Mice to Further Neurodegenerative Insults”
                Hana Dawson, PhD, Duke University

3:15–3:45 pm  “Safe Late Interventions for Too Much or Too Little Tau”
                Greg Cole, PhD, University of California, Los Angeles

3:45–4:00 pm  Break

4:00–4:30 pm  “Physiological Role of Tau and GSK-3b in Synaptic Plasticity Connecting to Tauopathies”
                Akihiko Takashima, PhD, RIKEN Institute

4:30–5:00 pm  “Tau as a Potential Therapeutic: A Long Overdue Target”
                Frank LaFerla, PhD, University of California, Irvine
Wednesday, March 30

9:00–9:30 am  “Which Animal Models for Tau Pathology?”  
Luc Buee, PhD, University of Lille

9:30–10:00 am  “Tau as a Signal Transduction Protein”  
Gloria Lee, PhD, University of Iowa

10:00–10:30 am  “From Abeta to Tau – The Role of Wnt Signaling in the Cascade”  
Simon Lovestone, PhD, University of London, King’s College

10:30–10:45 am  Break

10:45–11:15 am  TBA  
Karen Ashe, MD, PhD, University of Minnesota

11:15–12:00 pm  Workshop Summary and Discussion  
Lennart Mucke, MD, GIND and UCSF

12:00–1:00 pm  Speaker Luncheon

1:00 pm  Participants depart